Physician profile
Arslan Arshad
NPI 1891435376
$882.05
in general payments reported to CMS, 2019-2025
15 companies · $28.47 in 2025
The $28.47 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $13.26 · 2023: $686 · 2024: $154 · 2025: $28.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $869.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $868.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $194.75 | 2023-2024 | |
| Ucb, INC. | $130.98 | 2023 | Briviact, Fintepla |
| Astrazeneca Pharmaceuticals LP | $94.74 | 2023 | Fasenra, Andexxa |
| Eisai INC. | $82.09 | 2023 | |
| Alexion Pharmaceuticals, INC. | $81.74 | 2023-2024 | Soliris, Ultomiris |
| Takeda Pharmaceuticals U.S.A., INC. | $58.49 | 2023-2024 | Hyqvia |
| Abbvie INC. | $56.23 | 2023-2025 | Botox, Ubrelvy |
| Jazz Pharmaceuticals INC. | $43.37 | 2023-2024 | Epidiolex |
| Argenx US, INC. | $27.32 | 2023 | Vyvgart |
| Genentech USA, INC. | $23.12 | 2023 | Enspryng, Ocrevus |
| Acadia Pharmaceuticals INC | $21.05 | 2023 | Nuplazid |
| Biogen, INC. | $19.32 | 2024 | Skyclarys |
| Novartis Pharmaceuticals Corporation | $18.99 | 2024 | |
| Catalyst Pharmaceuticals, INC. | $16.60 | 2023 | Fycompa |
| Tanabe Pharma America, INC. | $13.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arslan Arshad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.